Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment

Government Dental College and Research Institute, Bangalore120 enrolled

Overview

The present study is designed as a single-centre, randomized, controlled clinical trial to evaluate and compare the clinical efficacy of autologous PRF, 1% alendronate (ALN) and 1.2% atorvastatin (ATV) gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis.

Background: Platelet-rich fibrin (PRF) is a second-generation platelet concentrate which releases various growth factors that promote tissue regeneration. Alendronate and Atorvastatin are known to inhibit osteoclastic bone resorption and were proposed to have osteostimulative properties by causing osteoblast differentiation in vivo and in vitro as shown by an increase in matrix formation. The aim of the present study is to evaluate and compare the efficacy of autologous PRF, 1% alendronate and 1.2% atorvastatin gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis. Methods: 120 CP subjects with IBD ≥3 mm deep and probing depth (PD) ≥5 mm, following scaling and root planing (SRP), were categorized into four treatment groups: 1) OFD 2) OFD with PRF 3) OFD with 1% ALN gel and 4) OFD with 1.2% ATV gel. Clinical parameters including site specific plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD) and relative attachment level (RAL) as well as percentage radiographic intrabony defect depth reduction (DDR) were recorded at baseline before surgery and 9 months post-operatively.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

120

Conditions

Chronic Periodontitis

Interventions

Open flap debridement (OFD)PROCEDURE

Oral prophylaxis followed by Open flap debridement (OFD)

OFD with PRFBIOLOGICAL

Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect

OFD with ALNDRUG

Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Systemically healthy patients with PDs ≥5mm or CALs ≥4 to 6mm and vertical bone loss ≥3 mm on intraoral periapical radiographs with no history of periodontal therapy or use of antibiotics in the preceding 6 months were included Exclusion Criteria: * Patients with a known systemic disease * Known or suspected allergy to the ALN/ bisphosphonates or ATV/statin group * On systemic ALN/ bisphosphonates or ATV/statin group * With aggressive periodontitis * Who used tobacco in any form * Alcoholics * Immunocompromised patients * And pregnant or lactating females were excluded from the study

Outcomes

Primary Outcomes

defect depth reduction (DDR)

Time frame: Change from baseline to 9 months

Secondary Outcomes

change in clinical attachment level (CAL)

Time frame: Change from baseline to 9 months

change in probing pocket depths (PPD)

Time frame: Change from baseline to 9 months

change in plaque index (PI)

Time frame: Change from baseline to 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.